ONCOLife’s Post

#News Update: Genmab to acquire Merus, expanding our late-stage oncology pipeline and accelerating sustainable growth. Genmab has entered into an agreement to acquire Merus, a clinical-stage biotech with a breakthrough therapy in Phase 3 development for patients with advanced cancers. This proposed acquisition would diversify our promising late-stage pipeline and strengthen our foundation for sustainable growth. Fully aligned with our long-term strategy and track record in antibody innovation, it reinforces our commitment to accelerating therapies into the clinic and making a meaningful impact on patients. Learn more at: http://gmab.ly/N0Aa50X3pr8 #Oncology #Biotech

Congratulations to Genmab and Merus on this transformational acquisition announcement! We're thrilled to see Petosemtamab's promising Phase 3 results culminate in this strategic partnership that has the potential to bring breakthrough therapy to patients with head and neck cancer. Crown Bioscience is proud to have contributed to Petosemtamab's development journey through our comprehensive preclinical research at our Netherlands facility. From the original compound selection via high-throughput screening to elucidating the mechanism of action, along with our PDX studies, we've been honored to support this innovative program from its earliest stages. This acquisition exemplifies how collaborative research partnerships can drive meaningful advances in oncology therapeutics. We look forward to seeing Petosemtamab's continued progress toward helping patients in need. Wishing both teams continued success as they work together to advance this promising therapy. Learn more about the original research - https://lnkd.in/eF_YKsWy

We’re excited to share that QUANTRO Therapeutics has extended its strategic collaboration with Boehringer Ingelheim for another two years. This builds on the successful completion of a major high-throughput screening (HTS) campaign and identification of attractive hits for further development. Together, we aim to develop first-in-class drug candidates targeting transcription factors to address high unmet needs in cancer patients. Under the agreement, QUANTRO is eligible for milestone payments of up to €500M. Meet us at BIO-Europe 2025 in Vienna (Nov 3–5) to learn more about how our time-resolved transcriptomics platform is redefining what’s possible in cancer drug discovery. See the full press release here: https://lnkd.in/dzV2XNjE

Our paper shows how The Responder Lab uses oncology omics data in trials to: 1) Define a gold standard of responders/non-responders 2) Predict which patients are responders, with over 82% accuracy This has vast implications in oncology trials, from patient selection to creating robust biomarkers of response - Not to mention the potential to resurrect failed trials. More detailed info from the paper will be shared soon! https://lnkd.in/e7kcyPPX

Driving innovation in small-molecule oncology drugs! Ever wonder how cancer treatment has advanced from a “no treatment” diagnosis to today’s targeted therapies? The answer lies in the incredible evolution of small-molecule drugs. This article by C&EN, featuring Lonza’s insights, takes us on a journey through the past, present, and future of small-molecule oncology. It’s a fascinating look at how scientific breakthroughs have enabled drugs to move beyond traditional models. Read about how specialized partners and advanced technologies are helping to accelerate innovation and shape a future where cancer diagnoses are a solvable challenge. Read the full article: https://ow.ly/3qSi30sQh8g #Pharma #Innovation #DrugDevelopment #Lonza

NEW: Iambic Therapeutics reported its first clinical data over the weekend at a cancer medical conference in Berlin. CEO Thomas Miller said it places Iambic, the San Diego biotech startup with now just over 100 employees, among a small group of AI-focused biotechs. “There’s not many who have made it to clinic,” he said in an interview. “There are not many that, once in clinic, have shown data. And there’s even fewer that have shown data and have been able to really stand proudly by that data.” My latest for Endpoints News: https://lnkd.in/e-_eKzQg

At the 19th Drug Discovery Strategic Summit, Ginette Serrero, CEO of Precision Antibody, delivered an insightful session on Novel Target Identification and Antibody-Drug Conjugate Development for Cancers with Unmet Targeted Therapy Needs — reminding us that innovation is most powerful when it’s purpose-driven. Her message echoed a powerful truth: every breakthrough begins with the courage to rethink the targets we pursue. Honored to highlight pioneers like her who are shaping the next wave of precision oncology. #DDSS2025 #DrugDiscovery #OncologyInnovation #PrecisionMedicine #AntibodyTherapeutics #LifeSciences #BiotechLeadership #AgileFalconStrategicGroup

Our bispecific antibody research began with a clear mission: to deliver new treatment options to patients in need. That mission guided every step—from early discovery to clinical development—and through collaboration, it became a reality. Watch our panel discussion on how we’re driven by the urgency to help patients with the fewest options— learning from our experiences to set the stage for future innovation in oncology research. https://bit.ly/43dz1aB #JNJOncology

I am delighted to share that my review article has been published in Molecules (MDPI). This work reflects our ongoing efforts in advancing research within the field of pharmaceutical sciences. Our review article titled “Coumarin Derivatives as Anti cancer Agents: Mechanistic Landscape with an Emphasis on Breast Cancer” This work explores the promising therapeutic role of coumarin derivatives against cancer, especially breast cancer, by diving deep into their diverse molecular mechanisms. Feeling grateful for the guidance and teamwork. 📌 Read the publication here: https://lnkd.in/gdgruVF6 #Research #Publication #MoleculesMDPI #BreastCancer #Coumarin #AnticancerAgents #PharmaceuticalSciences #DrugDiscovery

🔬 At AACR 2024, Blueprint Medicines presented how Cellecta’s Genome-Wide CRISPR Knockout Library helped uncover Rb and p16 as key biomarkers linked to response to BLU-222, a selective CDK2 inhibitor. Another example of how powerful CRISPR tools accelerate precision oncology breakthroughs. Read the full poster: https://lnkd.in/gGp-xVb3 #CRISPRScreening #CancerResearch #CDK2 #FunctionalGenomics #AACR2024 #Cellecta